Tag : Biotherapeutics

Latest News

Riassunto: SAB Biotherapeutics annuncia la prima somministrazione a un paziente di SAB-185 per il trattamento di COVID-19 nell’ambito della sua sperimentazione clinica di Fase 1b

Newsemia
SIOUX FALLS, Dakota del Sud–(BUSINESS WIRE)–SAB Biotherapeutics (SAB), una società impegnata nello sviluppo clinico di prodotti biofarmaceutici che sta sviluppando un’innovativa piattaforma per immunoterapie per...
Latest News

SAB Biotherapeutics gibt Gabe von SAB-185 an den ersten Patienten als Behandlung von COVID-19 in klinischer Studie der Phase 1b bekannt

Newsemia
SIOUX FALLS, South Dakota–(BUSINESS WIRE)–SAB Biotherapeutics announces the first patient dosed in its Phase 1B study evaluating SAB-185, the second study initiated this month for...
Latest News

Samenvatting: SAB Biotherapeutics kondigt de eerste patiënt aan die in fase 1b van het klinisch onderzoek van SAB-185 voor de behandeling van COVID-19 wordt gedoseerd

Newsemia
SIOUX FALLS, SD–(BUSINESS WIRE)–SAB Biotherapeutics (SAB), een biofarmaceutisch bedrijf in de klinische fase dat een nieuw immunotherapie platform ontwikkelt om gerichte polyklonale antilichamen te produceren,...
Latest News

Ridgeback Biotherapeutics LP Announces Priority Review of Biologics License Application for ansuvimab Ebola Treatment

Newsemia
MIAMI–(BUSINESS WIRE)–Ridgeback Biotherapeutics LP (“Ridgeback”), a biotechnology company experienced in antiviral drug development, today announced the U.S. Food and Drug Administration (FDA) has accepted the...
Latest News

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

Newsemia
Avacta Group plc, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co.Ltd and AffyXell Therapeutics. Source link...
Latest News

Avacta successfully generates several highly specific Affimer reagents for COVID-19 antigen rapid test ahead of schedule as part of Cytiva partnership

Newsemia
Avacta Group plc is pleased to announce that it has successfully generated multiple Affimer reagents that bind the SARS-COV-2 viral antigen. Source link...
Latest News

RELIEF THERAPEUTICS Holding SA Announces Divestment of its Subsidiary Relief Therapeutics SA to Sonnet BioTherapeutics, Inc. to Ensure the Development of Atexakin Alpha (Interleukin-6)

Newsemia
GENEVA–(BUSINESS WIRE)–RELIEF THERAPEUTICS Holding SA (SIX-RLF, “Relief” or the “Company”) announces today that it has executed a binding Share Exchange Agreement (the “Agreement”) with Sonnet...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World